Prot #1801: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ß) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Project: Research project

Project Details

StatusActive
Effective start/end date2/28/202/28/23

Funding

  • Actuate Therapeutics, Inc. (Prot #1801)